Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy

Abstract Background Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently mutated in several cancer types, but its role...

Full description

Bibliographic Details
Main Authors: Junyu Long, Dongxu Wang, Xu Yang, Anqiang Wang, Yu Lin, Mingjun Zheng, Haohai Zhang, Xinting Sang, Hanping Wang, Ke Hu, Haitao Zhao
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Medicine
Subjects:
NOTCH4
Immune checkpoint inhibitor
Clinical benefit
Objective response rate
Online Access:https://doi.org/10.1186/s12916-021-02031-3

Internet

https://doi.org/10.1186/s12916-021-02031-3

Similar Items